Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Intellia Therapeutics, Inc., Revolution Medicines or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Intellia Therapeutics, Inc., Revolution Medicines and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Intellia Therapeutics, Inc., Revolution Medicines and Inc.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Latest Biotechnology and Intellia Therapeutics, Inc., Revolution Medicines, Inc. Stock News

As of September 1, 2026, Intellia Therapeutics, Inc. had a $1.8 billion market capitalization, compared to the Biotechnology median of $282.5 million. Intellia Therapeutics, Inc.’s stock is up 41.6% in 2026, down 3.5% in the previous five trading days and up 11.71% in the past year.

Currently, Intellia Therapeutics, Inc. does not have a price-earnings ratio. Intellia Therapeutics, Inc.’s trailing 12-month revenue is $59.5 million with a -672.2% net profit margin. Year-over-year quarterly sales growth most recently was -45.8%. Analysts expect adjusted earnings to reach $-3.151 per share for the current fiscal year. Intellia Therapeutics, Inc. does not currently pay a dividend.

As of September 1, 2026, Revolution Medicines, Inc. had a $45.0 billion market cap, putting it in the 93rd percentile of all stocks. Revolution Medicines, Inc.’s stock is up 163.7% in 2026, down 2.5% in the previous five trading days and up 452.73% in the past year.

Currently, Revolution Medicines, Inc. does not have a price-earnings ratio. Revolution Medicines, Inc.’s trailing 12-month revenue is $0.0 million with a % net profit margin. As of September 1, 2026, Revolution Medicines, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-9.748 per share for the current fiscal year. Revolution Medicines, Inc. does not currently pay a dividend.

How We Compare Intellia Therapeutics, Inc., Revolution Medicines and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Intellia Therapeutics, Inc., Revolution Medicines and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Intellia Therapeutics, Inc., Revolution Medicines and Inc. Stock Value Grades

Company	Ticker	Value
Intellia Therapeutics, Inc.	NTLA	F
Revolution Medicines, Inc.	RVMD	na

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Intellia Therapeutics, Inc. has a Value Score of 9, which is Ultra Expensive. Revolution Medicines, Inc. does not have a meaningful Value Score.

The Value Stock Winner: No Clear Winner

Neither Intellia Therapeutics, Inc., Revolution Medicines or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Intellia Therapeutics, Inc., Revolution Medicines or Inc. is the better investment when it comes to value.

Intellia Therapeutics, Inc., Revolution Medicines and Inc.’s Quality Grades

Company	Ticker	Quality
Intellia Therapeutics, Inc.	NTLA	D
Revolution Medicines, Inc.	RVMD	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Intellia Therapeutics, Inc. has a Quality Score of 27, which is Weak. Revolution Medicines, Inc. has a Quality Score of 7, which is Very Weak.

The Quality Stock Winner: No Clear Winner

Neither Intellia Therapeutics, Inc., Revolution Medicines or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Intellia Therapeutics, Inc., Revolution Medicines or Inc. is the better investment when it comes to quality.

Intellia Therapeutics, Inc., Revolution Medicines and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Intellia Therapeutics, Inc.	NTLA	D
Revolution Medicines, Inc.	RVMD	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Intellia Therapeutics, Inc. has a Earnings Estimate Score of 37, which is Negative. Revolution Medicines, Inc. has a Earnings Estimate Score of 7, which is Very Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Intellia Therapeutics, Inc., Revolution Medicines or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Intellia Therapeutics, Inc., Revolution Medicines or Inc. is the better investment when it comes to estimate revisions.

Other Intellia Therapeutics, Inc., Revolution Medicines and Inc. Grades

In addition to Quality, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Intellia Therapeutics, Inc., Revolution Medicines and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Intellia Therapeutics, Inc., Revolution Medicines or Inc. Stock?

Overall, Intellia Therapeutics, Inc. stock has a Value Score of 9, Estimate Revisions Score of 37 and Quality Score of 27.

Revolution Medicines, Inc. stock has a Value Score of , Estimate Revisions Score of 7 and Quality Score of 7.

Comparing Intellia Therapeutics, Inc., Revolution Medicines and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.